The present invention provides compounds, compositions thereof, and methods of using the same.

The present disclosure provides a method to treat or ameliorate vascular malformations, developmental abnormalities of one or more types of blood or lymphatic vessels. These are rare disorders with life-long risk of high morbidity including cosmetic concerns, pain, infection, pulmonary emboli, bleeding and even death. Treatment is difficult, and there is growing interest in improved therapies. The disclosure provides specific compounds that are inhibitors of Notch receptor signaling. In some embodiments, the compounds disclosed are gamma secretase inhibitors (GSIs).

The present invention addresses the problem of providing a novel orally ingested composition that contains a substance which is not conventionally known as an active component of a composition for improving sleep, and particularly, that can be easily taken orally and can improve sleep safely and easily. The present invention pertains to an orally ingested composition, particularly a food composition, for improving sleep and containing a choline ester as an active component In the present invention, the choline ester may be derived from an edible plant such as the fruit of the species Solanum melongena of the genus Solanum of the family Solanaceae and/or the green shoot of the tribe Bambuseae of the subfamily Bambusoideae of the family Poaceae.

The present invention addresses the problem of providing a novel orally ingested composition that contains a substance which is not conventionally known as an active component of a composition for improving sleep, and particularly, that can be easily taken orally and can improve sleep safely and easily. The present invention pertains to an orally ingested composition, particularly a food composition, for improving sleep and containing a choline ester as an active component In the present invention, the choline ester may be derived from an edible plant such as the fruit of the species Solanum melongena of the genus Solanum of the family Solanaceae and/or the green shoot of the tribe Bambuseae of the subfamily Bambusoideae of the family Poaceae.

Ophthalmic formulations for treatment of night vision disturbance syndrome (NVD) are presented and preferably comprise brimonidine, rivastigmine, and/or galantamine at very low concentrations. Such formulations unexpectedly provided acute and transient therapeutic effect to alleviate one or more symptoms associated with NVD.

Ophthalmic formulations for treatment of night vision disturbance syndrome (NVD) are presented and preferably comprise brimonidine, rivastigmine, and/or galantamine at very low concentrations. Such formulations unexpectedly provided acute and transient therapeutic effect to alleviate one or more symptoms associated with NVD.

Provided herein are methods of preventing, reducing, ameliorating, mitigating, inhibiting, treating and/or reversing a neurodevelopmental disorder related to prenatal maternal immune activation in an individual in need thereof comprising administering to said individual an agent that increases the level of epoxy-fatty acids wherein said individual experienced maternal immune activation one or more times during gestation. Also provided herein are methods of preventing, reducing, ameliorating, mitigating, inhibiting treating and/or reversing schizophrenia or autism spectrum disorder an individual comprising administering to said individual an agent that increases the level of epoxy-fatty acids.

Provided herein are methods of preventing, reducing, ameliorating, mitigating, inhibiting, treating and/or reversing a neurodevelopmental disorder related to prenatal maternal immune activation in an individual in need thereof comprising administering to said individual an agent that increases the level of epoxy-fatty acids wherein said individual experienced maternal immune activation one or more times during gestation. Also provided herein are methods of preventing, reducing, ameliorating, mitigating, inhibiting treating and/or reversing schizophrenia or autism spectrum disorder an individual comprising administering to said individual an agent that increases the level of epoxy-fatty acids.

An oral mucosal carrier comprising a combination of two different viscosity dimethicone components, wherein the difference between the two different viscosity dimethicone components is about 2.0 million cP or greater; and comprising at least one active agent.

An oral mucosal carrier comprising a combination of two different viscosity dimethicone components, wherein the difference between the two different viscosity dimethicone components is about 2.0 million cP or greater; and comprising at least one active agent.